CBL (E3 ubiquitin-protein ligase CBL) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
E3 ubiquitin-protein ligase that acts as a negative regulator of many signalling pathways by mediating ubiquitination of cell surface receptors. Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognises activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and mediates their ubiquitination to terminate signalling. Recognises membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Ubiquitinates EGFR and SPRY2. Involved in LAG3-mediated inhibition of TCR signalling: following ligand-binding to LAG3, catalyses 'Lys-63'-linked ubiquitination of LAG3, unleashing the LAG3 C-terminus from the membrane, and initiating a signalling that prevents TCR activation. Location: Cytoplasm; Cell membrane; Cell projection, cilium; Golgi apparatus (UniProt). Locus 11q23.3 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.81 with myeloproliferative neoplasm (MONDO_0020076)
- Leukaemia: Open Targets association 0.80 with leukaemia (MONDO_0005059)
- Skin cancer: Open Targets association 0.58 with skin cancer (MONDO_0002898)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Ovarian cancer: Open Targets association 0.56 with ovarian cancer (MONDO_0008170)
- Sarcomas: Open Targets association 0.52 with sarcoma (MONDO_0005089)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"CBL" OR ABSTRACT:"CBL" OR TITLE:"Cbl proto-oncogene" OR ABSTRACT:"Cbl proto-oncogene" OR TITLE:"E3 ubiquitin-protein ligase CBL" OR ABSTRACT:"E3 ubiquitin-protein ligase CBL" OR TITLE:"RNF55" OR ABSTRACT:"RNF55" OR TITLE:"c-Cbl" OR ABSTRACT:"c-Cbl" OR TITLE:"CBL2" OR ABSTRACT:"CBL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CBL, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cbl.json. Licence CC BY-NC 4.0.